Quince Therapeutics

Quince Therapeutics

Dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases

Founded 2012

South San Francisco, United States 25 employees Post-IPO Equity Biotechnology, Health Care +1

Quince Therapeutics is a late-stage biotechnology company aiming to leverage the patient’s own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, utilizes the proprietary Autologous Intracellular Drug Encapsulation (AIDE) technology platform, which encapsulates a drug into the patient’s own red blood cells. This unique approach offers potential benefits such as improved tolerability, enhanced tissue distribution, reduced immunogenicity, and prolonged circulating half-life. EryDex, containing dexamethasone sodium phosphate (DSP) encapsulated in autologous red blood cells, targets the treatment of the rare pediatric neurodegenerative disease, Ataxia-Telangiectasia (A-T). The company is currently enrolling patients in the pivotal Phase 3 NEAT study, with an expected assessment in the fourth quarter of 2025. If the results are positive, a New Drug Application (NDA) submission to the FDA and a Marketing Authorization (MAA) submission to the European Medicines Agency (EMA) are anticipated in 2026. Quince was granted Fast Track designation by the FDA for the EryDex System, acknowledging its potential to address A-T's high unmet medical need. Quince Therapeutics was founded in 2012 and operates in the biotechnology, health care, and pharmaceutical industries. Their last known investment was a Post-IPO Equity investment at 13 December 2019.

Funding Stage	Amount	Investors	Date
Post IPO Equity	Undisclosed	-	13 Dec 2019
Series B	Undisclosed	-	31 May 2018
Debt Financing	Undisclosed	-	14 Apr 2017
Series A	Undisclosed	-	06 Jan 2016
Seed	Undisclosed	-	06 Oct 2014
Grant	Undisclosed	-	12 Jun 2014

Funding Stage

Amount

Investors

Lead Investors

Date

Post IPO Equity

Undisclosed

13 Dec 2019

Series B

Undisclosed

31 May 2018

Debt Financing

Undisclosed

14 Apr 2017

Series A

Undisclosed

06 Jan 2016

Seed

Undisclosed

06 Oct 2014

Grant

Undisclosed

12 Jun 2014

FAQ About Quince Therapeutics

Dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases

Quince Therapeutics was founded in 2012.

Quince Therapeutics is headquartered in South San Francisco, United States.

Quince Therapeutics operates in Biotechnology, Health Care and Pharmaceutical. Its work centres on Rare diseases treatment, Neurodegenerative diseases, Drug delivery technology and Clinical trials.

Quince Therapeutics has approximately 25 employees.

Quince Therapeutics has completed 6 funding rounds. The latest funding stage is Post-IPO Equity.

Top alternatives and competitors to Quince Therapeutics include Quince Therapeutics SpA, Akari Therapeutics, Plc, Emmaus Life Sciences, Inc, Brainstorm Cell Therapeutics, VG Life Sciences. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.

Quince Therapeutics and Quince Therapeutics SpA are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

General Information

Discover More

About Quince Therapeutics

Funding Rounds & Investors (6)

Quince Therapeutics Alternatives & Competitors

FAQ About Quince Therapeutics